The influence of the surfactants of sodium lauryl sulfate (SLS) and Tween 80 on carbamazepine–nicotinamide (CBZ–NIC) cocrystal solubility and dissolution behaviour has been studied in this work. The solubility of the CBZ–NIC cocrystal was determined by measuring the eutectic concentrations of the drug and the coformer. Evolution of the intrinsic dissolution rate (IDR) of the CBZ–NIC cocrystal was monitored by the UV imaging dissolution system during dissolution. Experimental results indicated that SLS and Tween 80 had little influence upon the solubility of the CBZ–NIC cocrystal but they had totally opposite effects on the IDR of the CBZ–NIC cocrystal during dissolution. SLS significantly increased the IDR of the CBZ–NIC cocrystal while Tween 80 decreased its IDR.
References
[1]
Qiao, N.; Li, M.; Schlindwein, W.; Malek, N.; Davies, A.; Trappitt, G. Pharmaceutical cocrystals: An overview. Int. J. Pharm. 2011, 419, 1–11, doi:10.1016/j.ijpharm.2011.07.037.
[2]
Aakeroy, C.B.; Fasulo, M.; Schultheiss, N.; Desper, J.; Moore, C. Structural competition between hydrogen bonds and halogen bonds. J. Am. Chem. Soc. 2007, 129, 13772–13773, doi:10.1021/ja073201c.
[3]
Childs, S.L.; Chyall, L.J.; Dunlap, J.T.; Smolenskaya, V.N.; Stahly, B.C.; Stahly, G.P. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J. Am. Chem. Soc. 2004, 126, 13335–13342, doi:10.1021/ja048114o. 15479089
[4]
Greco, K.; Bogner, R. Solution-mediated phase transformation: Significance during dissolution and implications for bioavailability. J. Pharm. Sci. 2012, 101, 2996–3018, doi:10.1002/jps.23025.
[5]
Shiraki, K.; Takata, N.; Takano, R.; Hayashi, Y.; Terada, K. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm. Res. 2008, 25, 2581–2592, doi:10.1007/s11095-008-9676-2.
[6]
McNamara, D.; Childs, S.; Giordano, J.; Iarriccio, A.; Cassidy, J.; Shet, M.; Mannion, R.; O’Donnell, E.; Park, A. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm. Res. 2006, 23, 1888–1897, doi:10.1007/s11095-006-9032-3.
[7]
Basavoju, S.; Bostrom, D.; Velaga, S. Indomethacin-saccharin cocrystal: Design, synthesis and preliminary pharmaceutical characterization. Pharm. Res. 2008, 25, 530–541, doi:10.1007/s11095-007-9394-1.
[8]
Qiao, N.; Wang, K.; Schlindwein, W.; Davies, A.; Li, M. In situ monitoring of carbamazepine–nicotinamide cocrystal intrinsic dissolution behaviour. Eur. J. Pharm. Biopharm. 2013, 83, 415–426, doi:10.1016/j.ejpb.2012.10.005.
[9]
Simonelli, A.P.; Mehta, S.C.; Higuchi, W.I. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J. Pharm. Sci. 1970, 59, 633–638, doi:10.1002/jps.2600590512.
[10]
Gift, A.D.; Luner, P.E.; Luedeman, L.; Taylor, L.S. Influence of polymeric excipients on crystal hydrate formation kinetics in aqueous slurries. J. Pharm. Sci. 2008, 97, 5198–5211, doi:10.1002/jps.21379.
[11]
Katzhendler, I.; Azoury, R.; Friedman, M. Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methylcellulose. J. Control. Release 1998, 54, 69–85, doi:10.1016/S0168-3659(98)00002-9.
[12]
Jinno, J.; Oh, D.-M.; Crison, J.R.; Amidon, G.L. Dissolution of ionizable water-insoluble drugs: The combined effect of ph and surfactant. J. Pharm. Sci. 2000, 89, 268–274, doi:10.1002/(SICI)1520-6017(200002)89:2<268::AID-JPS14>3.0.CO;2-F.
[13]
Aburub, A.; Risley, D.S.; Mishra, D. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe. Int. J. Pharm. 2008, 347, 16–22, doi:10.1016/j.ijpharm.2007.06.018.
[14]
He, Y.; Yalkowsky, S.H. Solubilization of monovalent weak electrolytes by micellization or complexation. Int. J. Pharm. 2006, 314, 15–20, doi:10.1016/j.ijpharm.2006.01.039.
[15]
Seedher, N.; Kanojia, M. Micellar solubilization of some poorly soluble antidiabetic drugs: A technical note. AAPS PharmSciTech 2008, 9, 431–436, doi:10.1208/s12249-008-9057-5.
[16]
Li, P.; Tabibi, S.E.; Yalkowsky, S.H. Combined effect of complexation and ph on solubilization. J. Pharm. Sci. 1998, 87, 1535–1537, doi:10.1021/js9801889.
[17]
Remenar, J.F.; Peterson, M.L.; Stephens, P.W.; Zhang, Z.; Zimenkov, Y.; Hickey, M.B. Celecoxib:Nicotinamide dissociation: Using excipients to capture the cocrystal’s potential. Mol. Pharm. 2007, 4, 386–400, doi:10.1021/mp0700108.
[18]
Huang, N.; Rodriguez-Hornedo, N. Engineering cocrystal solubility, stability, and phmax by micellar solubilization. J. Pharm. Sci. 2011, 100, 5219–5234, doi:10.1002/jps.22725.
[19]
Huang, N.; Rodriguez-Hornedo, N. Engineering cocrystal thermodynamic stability and eutectic points by micellar solubilization and ionization. CrystEngComm 2011, 13, 5409–5422, doi:10.1039/c1ce05381g.
[20]
Huang, N.; Rodriguez-Hornedo, N. Effect of micellar solubilization on cocrystal solubility and stability. Cryst. Growth Des. 2010, 10, 2050–2053, doi:10.1021/cg1002176.
[21]
Ostergaard, J.; Meng-Lund, E.; Larsen, S.; Larsen, C.; Petersson, K.; Lenke, J.; Jensen, H. Real-time UV imaging of nicotine release from transdermal patch. Pharm. Res. 2010, 27, 2614–2623, doi:10.1007/s11095-010-0257-9.
[22]
Ostergaard, J.; Ye, F.; Rantanen, J.; Yaghmur, A.; Larsen, S.W.; Larsen, C.; Jensen, H. Monitoring lidocaine single-crystal dissolution by ultraviolet imaging. J. Pharm. Sci. 2011, 100, 3405–3410, doi:10.1002/jps.22532.
[23]
Meyer, M.C.; Straughn, A.B.; Jarvi, E.J.; Wood, G.C.; Pelsor, F.R.; Shah, V.P. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res. 1992, 9, 1612–1616, doi:10.1023/A:1015872626887.
[24]
Berry, D.J.; Seaton, C.C.; Clegg, W.; Harrington, R.W.; Coles, S.J.; Horton, P.N.; Hursthouse, M.B.; Storey, R.; Jones, W.; Friscic, T.; et al. Applying hot-stage microscopy to co-crystal screening: A study of nicotinamide with seven active pharmaceutical ingredients. Cryst. Growth Des. 2008, 8, 1697–1712, doi:10.1021/cg800035w.
[25]
Good, D.J.; Rodriguez-Hornedo, N. Solubility advantage of pharmaceutical cocrystals. Cryst. Growth Des. 2009, 9, 2252–2264, doi:10.1021/cg801039j.
[26]
Good, D.J.; Rodriguez-Hornedo, N. Cocrystal eutectic constants and prediction of solubility behavior. Cryst. Growth Des. 2010, 10, 1028–1032, doi:10.1021/cg901232h.
[27]
Bethune, S.J.; Huang, N.; Jayasankar, A.; Rodriguez-Hornedo, N. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst. Growth Des. 2009, 9, 3976–3988, doi:10.1021/cg9001187.
[28]
Higuchi, W.I.; Mir, N.A.; Desai, S.J. Dissolution rates of polyphase mixtures. J. Pharm. Sci. 1965, 54, 1405–1410, doi:10.1002/jps.2600541003.
Sanghvi, R.; Evans, D.; Yalkowsky, S.H. Stacking complexation by nicotinamide: A useful way of enhancing drug solubility. Int. J. Pharm. 2007, 336, 35–41, doi:10.1016/j.ijpharm.2006.11.025.
[31]
Chen, L.; Wesley, J.; Bhattachar, S.; Ruiz, B.; Bahash, K.; Babu, S. Dissolution behavior of a poorly water soluble compound in the presence of tween 80. Pharm. Res. 2003, 20, 797–801, doi:10.1023/A:1023493821302.
